Verizon's dividend yield and Merck’s growth lead the Dow Dogs. Read why they’re set for solid returns, with other top picks ...

Highlights,Citigroup revised its price target for Merck & Co., adjusting it from $125 to $115 while maintaining an optimistic ...

We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before ...

Highlights,Price target adjustment,Citigroup analysts revised Merck’s target from $125.00 to $115.00.,Stock performance trends,The company’s stock has fluctuated within a defined price range over the ...

Robert F Kennedy Jr's nomination now will face a full senate vote, despite concerns about the work he's done to sow doubts around vaccine safety and his potential to profit off lawsuits over ...

Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...

Merck & Co Inc (Symbol: MRK) presently has a stellar rank, in the top 10% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by ...

Merck swung to a quarterly profit as sales grew to beat Wall Street's estimates, though the drug company's outlook for 2025 and a slide in sales of its HPV vaccine, Gardasil, hit shares. The ...

Merck (MRK) came out with quarterly earnings of $1.72 per share, beating the Zacks Consensus Estimate of $1.69 per share. This compares to earnings of $0.03 per share a year ago. These figures are ...

Merck swung to a fourth-quarter profit as sales grew and even exceeded Wall Street's estimates, boosted in part by the performance of top asset Keytruda. The drug company logged net income of $3.74 ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other stocks. Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate ...